{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T17:58:37Z","timestamp":1770746317760,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"XY Therapeutics"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Infertility is a common problem globally and impaired semen quality is responsible for up to 40% of all cases. Almost all infertile couples are treated with either insemination or assisted reproductive techniques (ARTs) independent of the etiology of infertility because no medical treatment exists. Denosumab is an antibody that blocks RANKL signaling and inhibition of testicular RANKL signaling has been suggested to improve semen quality in a pilot study. This RCT aims to assess whether treatment with denosumab can improve spermatogenesis in infertile men selected by serum AMH as a positive predictive biomarker. This paper describes the design of the study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods\/design<\/jats:title>\n                <jats:p>FITMI is a sponsor-investigator-initiated, double-blinded, placebo-controlled 1:1, single-center, randomized clinical trial. Subjects will be randomized to receive either a single-dose denosumab 60\u00a0mg subcutaneous injection or placebo. The study will be carried out at the Department of Growth and Reproduction, Copenhagen University Hospital, Rigshospitalet, Copenhagen. The primary outcome of the study is defined as the difference in sperm concentration (millions pr. mL) one spermatogenesis (80\u00a0days) after inclusion.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>We describe a protocol for a planned RCT aimed at evaluating whether treatment with denosumab can improve the semen quality in infertile men selected by using serum AMH as a positive predictive biomarker. The results will provide evidence crucial for future treatment in a patient group where there is a huge unmet need.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Clinical Trials.gov <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT05212337\">NCT05212337<\/jats:ext-link>. Registered on 14 January 2022.<\/jats:p>\n                <jats:p>EudraCT 2021\u2013003,451-42. Registered on 23 June 2021.<\/jats:p>\n                <jats:p>Ethical committee H-21040145. Registered on 23 December 2021.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-022-06478-4","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T10:03:01Z","timestamp":1655892181000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effect of a single-dose denosumab on semen quality in infertile men (the FITMI study): study protocol for a randomized controlled trial"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6658-5094","authenticated-orcid":false,"given":"Sam Kafai","family":"Yahyavi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rune","family":"Holt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Juel Mortensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f8rgen Holm","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels","family":"J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Juul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Blomberg Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,22]]},"reference":[{"issue":"2","key":"6478_CR1","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/humupd\/8.2.183","volume":"8","author":"T Huynh","year":"2002","unstructured":"Huynh T. Selected genetic factors associated with male infertility. Hum Reprod Update. 2002;8(2):183\u201398.","journal-title":"Hum Reprod Update"},{"issue":"2","key":"6478_CR2","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.beem.2010.08.006","volume":"25","author":"C Krausz","year":"2011","unstructured":"Krausz C. Male infertility: pathogenesis and clinical diagnosis. Best Pract Res Clin Endocrinol Metab. 2011;25(2):271\u201385.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"1","key":"6478_CR3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1152\/physrev.00017.2015","volume":"96","author":"NE Skakkebaek","year":"2016","unstructured":"Skakkebaek NE, Rajpert-De Meyts E, Buck Louis GM, Toppari J, Andersson A-M, Eisenberg ML, et al. Male reproductive disorders and fertility trends: influences of environment and genetic susceptibility. Physiol Rev. 2016;96(1):55\u201397.","journal-title":"Physiol Rev"},{"issue":"3","key":"6478_CR4","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1210\/jc.2017-01656","volume":"103","author":"M Blomberg Jensen","year":"2017","unstructured":"Blomberg Jensen M, Lawaetz JG, Petersen JH, Juul A, J\u00f8rgensen N. Effects of vitamin D supplementation on semen quality, reproductive hormones, and live birth rate: a randomized clinical trial. J Clin Endocrinol Metab. 2017;103(3):870\u201381.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"6478_CR5","doi-asserted-by":"publisher","first-page":"12436","DOI":"10.1096\/fj.202000061RR","volume":"34","author":"L B\u00f8llehuus Hansen","year":"2020","unstructured":"B\u00f8llehuus Hansen L, Kaludjerovic J, Nielsen JE, Rehfeld A, Poulsen NN, Ide N, et al. Influence of FGF23 and Klotho on male reproduction: Systemic vs direct effects. FASEB J. 2020;34(9):12436\u201349.","journal-title":"FASEB J"},{"key":"6478_CR6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.bone.2019.03.022","volume":"123","author":"L Juel Mortensen","year":"2019","unstructured":"Juel Mortensen L, Lorenzen M, Jorgensen N, Andersson A-M, Nielsen JE, Petersen LI, et al. Possible link between FSH and RANKL release from adipocytes in men with impaired gonadal function including Klinefelter syndrome. Bone. 2019;123:103\u201314.","journal-title":"Bone"},{"key":"6478_CR7","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nrendo.2013.262","volume":"10","author":"MB Jensen","year":"2014","unstructured":"Jensen MB. Vitamin D and male reproduction. Nat Rev Endocrinol. 2014;10:175\u201386.","journal-title":"Nat Rev Endocrinol."},{"key":"6478_CR8","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1210\/er.2007-0014","volume":"29","author":"AE Kearns","year":"2008","unstructured":"Kearns AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factor \u03baB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev. 2008;29:155\u201392.","journal-title":"Endocr Rev."},{"issue":"2","key":"6478_CR9","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1210\/er.2007-0014","volume":"29","author":"AE Kearns","year":"2007","unstructured":"Kearns AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factor \u03baB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev. 2007;29(2):155\u201392.","journal-title":"Endocr Rev"},{"issue":"2","key":"6478_CR10","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","volume":"93","author":"DL Lacey","year":"1998","unstructured":"Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93(2):165\u201376.","journal-title":"Cell"},{"issue":"2","key":"6478_CR11","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","volume":"89","author":"WS Simonet","year":"1997","unstructured":"Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, L\u00fcthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89(2):309\u201319.","journal-title":"Cell"},{"issue":"12","key":"6478_CR12","doi-asserted-by":"publisher","first-page":"5050","DOI":"10.1210\/endo.142.12.8536","volume":"142","author":"S Khosla","year":"2001","unstructured":"Khosla S. Minireview: The OPG\/RANKL\/RANK System. Endocrinology. 2001;142(12):5050\u20135.","journal-title":"Endocrinology"},{"issue":"8","key":"6478_CR13","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1517\/13543780903048929","volume":"18","author":"AD Anastasilakis","year":"2009","unstructured":"Anastasilakis AD, Toulis KA, Polyzos SA, Terpos E. RANKL inhibition for the management of patients with benign metabolic bone disorders. Expert Opin Investig Drugs. 2009;18(8):1085\u2013102.","journal-title":"Expert Opin Investig Drugs"},{"issue":"4","key":"6478_CR14","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/cen.12188","volume":"79","author":"P Makras","year":"2013","unstructured":"Makras P, Polyzos SA, Papatheodorou A, Kokkoris P, Chatzifotiadis D, Anastasilakis AD. Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis. Clin Endocrinol (Oxf). 2013;79(4):499\u2013503.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"6478_CR15","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.bone.2012.01.020","volume":"50","author":"P Schwarz","year":"2012","unstructured":"Schwarz P, Rasmussen AQ, Kvist TM, Andersen UB, J\u00f8rgensen NR. Paget\u2019s disease of the bone after treatment with Denosumab: A case report. Bone. 2012;50(5):1023\u20135.","journal-title":"Bone"},{"issue":"3","key":"6478_CR16","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1210\/jc.2013-3762","volume":"99","author":"SA Polyzos","year":"2014","unstructured":"Polyzos SA, Singhellakis PN, Naot D, Adamidou F, Malandrinou FC, Anastasilakis AD, et al. Denosumab Treatment for Juvenile Paget\u2019s disease: results from two adult patients with osteoprotegerin deficiency (\u201cBalkan\u201d mutation in the TNFRSF11BGene). J Clin Endocrinol Metab. 2014;99(3):703\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"6478_CR17","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/jbmr.1479","volume":"27","author":"S Papapoulos","year":"2012","unstructured":"Papapoulos S, Chapurlat R, Libanati C, Brandi ML, Brown JP, Czerwi\u0144ski E, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension. J Bone Miner Res. 2012;27(3):694\u2013701.","journal-title":"J Bone Miner Res"},{"issue":"6","key":"6478_CR18","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1210\/jc.2010-2784","volume":"96","author":"S Boonen","year":"2011","unstructured":"Boonen S, Adachi JD, Man Z, Cummings SR, Lippuner K, T\u00f6rring O, et al. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab. 2011;96(6):1727\u201336.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"6478_CR19","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/bcp.12798","volume":"81","author":"W Sohn","year":"2015","unstructured":"Sohn W, Lee E, Kankam MK, Egbuna O, Moffat G, Bussiere J, et al. An open-label study in healthy men to evaluate the risk of seminal fluid transmission of denosumab to pregnant partners. Br J Clin Pharmacol. 2015;81(2):362\u20139.","journal-title":"Br J Clin Pharmacol"},{"key":"6478_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.reprotox.2013.07.018","volume":"42","author":"JL Bussiere","year":"2013","unstructured":"Bussiere JL, Pyrah I, Boyce R, Branstetter D, Loomis M, Andrews-Cleavenger D, et al. Reproductive toxicity of denosumab in cynomolgus monkeys. Reprod Toxicol. 2013;42:27\u201340.","journal-title":"Reprod Toxicol"},{"issue":"6","key":"6478_CR21","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1093\/jn\/122.6.1338","volume":"122","author":"AM Uhland","year":"1992","unstructured":"Uhland AM, Kwiecinski GG, DeLuca HF. Normalization of serum calcium restores fertility in vitamin D-deficient male rats. J Nutr. 1992;122(6):1338\u201344.","journal-title":"J Nutr"},{"issue":"5","key":"6478_CR22","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1093\/jn\/119.5.741","volume":"119","author":"GG Kwiecinski","year":"1989","unstructured":"Kwiecinski GG, Petrie GI, DeLuca HF. Vitamin D is necessary for reproductive functions of the male rat. J Nutr. 1989;119(5):741\u20134.","journal-title":"J Nutr"},{"key":"6478_CR23","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jsbmb.2012.10.008","volume":"136","author":"A J\u00f8rgensen","year":"2013","unstructured":"J\u00f8rgensen A, Blomberg Jensen M, Nielsen JE, Juul A, Rajpert-De ME. Influence of vitamin D on cisplatin sensitivity in testicular germ cell cancer-derived cell lines and in a NTera2 xenograft model. J Steroid Biochem Mol Biol. 2013;136:238\u201346.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"10","key":"6478_CR24","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1593\/neo.121164","volume":"14","author":"M Blomberg Jensen","year":"2012","unstructured":"Blomberg Jensen M, J\u00f8rgensen A, Nielsen JE, Steinmeyer A, Leffers H, Juul A, et al. Vitamin D metabolism and effects on pluripotency genes and cell differentiation in testicular germ cell tumors in vitro and in vivo. Neoplasia. 2012;14(10):952-IN18.","journal-title":"Neoplasia"},{"issue":"1\u20132","key":"6478_CR25","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.mce.2013.06.036","volume":"377","author":"M Blomberg Jensen","year":"2013","unstructured":"Blomberg Jensen M, Lieben L, Nielsen JE, Willems A, J\u00f8rgensen A, Juul A, et al. Characterization of the testicular, epididymal and endocrine phenotypes in the Leuven Vdr-deficient mouse model: Targeting estrogen signalling. Mol Cell Endocrinol. 2013;377(1\u20132):93\u2013102.","journal-title":"Mol Cell Endocrinol"},{"issue":"1","key":"6478_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-22734-8","volume":"12","author":"M Blomberg Jensen","year":"2021","unstructured":"Blomberg Jensen M, Andreassen CH, J\u00f8rgensen A, et al. RANKL regulates male reproductive function. Nat Commun. 2021;12(1):1\u201315.","journal-title":"Nat Commun."},{"issue":"jan08 15","key":"6478_CR27","doi-asserted-by":"publisher","first-page":"7586","DOI":"10.1136\/bmj.e7586","volume":"346","author":"A-W Chan","year":"2013","unstructured":"Chan A-W, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346(jan08 15):7586.","journal-title":"BMJ"},{"key":"6478_CR28","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) ICH Harmonised Guideline Integrated Addendum to ICH E6(R1): Guideline for good clinical practice E6(R2). 2016."},{"issue":"13\u201314","key":"6478_CR29","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1002\/sim.4780131308","volume":"13","author":"DL Demets","year":"1994","unstructured":"Demets DL, Lan KKG. Interim analysis: The alpha spending function approach. Stat Med. 1994;13(13\u201314):1341\u201352.","journal-title":"Stat Med"},{"key":"6478_CR30","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2147\/CIA.S14565","volume":"6","author":"RA Adler","year":"2011","unstructured":"Adler RA, Gill RS. Clinical utility of denosumab for treatment of bone loss in men and women. Clin Interv Aging. 2011;6:119\u201324.","journal-title":"Clin Interv Aging."},{"issue":"6","key":"6478_CR31","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1093\/humrep\/dem046","volume":"22","author":"J Boivin","year":"2007","unstructured":"Boivin J, Bunting L, Collins JA, Nygren KG. International estimates of infertility prevalence and treatment-seeking: potential need and demand for infertility medical care. Hum Reprod. 2007;22(6):1506\u201312.","journal-title":"Hum Reprod"},{"issue":"4","key":"6478_CR32","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1093\/humupd\/dmh028","volume":"10","author":"B Lunenfeld","year":"2004","unstructured":"Lunenfeld B. Infertility in the third millennium: implications for the individual, family and society: Condensed Meeting Report from the Bertarelli Foundation\u2019s Second Global Conference. Hum Reprod Update. 2004;10(4):317\u201326.","journal-title":"Hum Reprod Update"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06478-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-022-06478-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06478-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T10:06:31Z","timestamp":1655892391000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-06478-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,22]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["6478"],"URL":"https:\/\/doi.org\/10.1186\/s13063-022-06478-4","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,22]]},"assertion":[{"value":"31 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study will be carried out to include the protection of human subjects according to the 2008 Declaration of Helsinki and following Good Clinical Practice Guidelines. After verbal and written information is given to potential participants, informed consent will be obtained. All risk or safety issues will be reported to the principal investigators, who will take any necessary further steps. The study has been approved by the National Ethics Committees of the capital region of Denmark (H-21040145) and the Danish Medicines Agency (EudraCT no: 2021\u2013003451-42) which qualified for registration in the ClinicalTrials.gov database (identifier NCT05212337). Major modifications, such as changes to outcome measures or change of design, will be sent to and evaluated by the National Ethics Committees of the capital region of Denmark, Good Clinical Practice unit, and Danish Medicines Agency.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests except that Martin Blomberg Jensen also is the CEO of \u201cXY Therapeutics.\u201d","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"525"}}